Consulto Secures CHF 400’000 Innosuisse Innovation Grant

EPFL startup, Consulto, has been awarded a CHF 400’000 grant in collaboration with EPFL, CHUV, the University of Basel, and Groupe Mutuel to revolutionise patient care pathway design and implementation.

This new funding represents a significant milestone for the startup as it accelerates the development of ConsultoPATH. An AI pathway designer that helps healthcare organisations design and implement customised care pathways and personalised patient journeys.

The Innosuisse grant also facilitates a strategic partnership for Consulto team, CHUV’s Rheumatology Department, the Research and Analytic Services University Hospital Basel (USB), and the Value-Based Care team of Groupe Mutuel.

The collaboration enables the development of an AI Patient Pathway Designer that curates tailored care pathways for better patient outcomes and more efficient use of healthcare resources. This promotes value-based care through delivering outcomes that matter most to patients relative to the cost and ensuring that healthcare services are coordinated and patient-centred.

Consulto will put its first application on improving the patient journey for patients suffering from low back pain, focusing on secondary prevention of chronification through optimising referral processes and care cycle management.

Prof. Dr. Thomas Hügle, Head of Rheumatology,

“Digital Clinical Pathways are becoming the backbone of healthcare. Consulto understood this and created a solution to streamline digital pathways in order to optimise processes and communication among interdisciplinary health care professionals and patients. Such tools are urgently necessary to respond to the lack of time, resources and exploding costs in health care”, said Prof. Dr. Thomas Hügle, Head of Rheumatology at CHUV.

Traditional methods of designing care pathways are costly and slow, taking between three and nine months for hospitals to implement. Additionally, these pathways are typically static and designed for managing single disease areas, leaving gaps for patients with multiple conditions.

Consulto’s AI technology, on the other hand, enables the development of dynamic, evidence-based care pathways that adapt to real-time data and patient needs. Consulto’s solution can address multiple conditions, filling gaps left by single-disease pathways, and leverages the use of data from electronic medical records and insurance claims.

This technology enables the creation of a personalised patient journey, outlining all steps a patient undergoes during a care cycle, including consultations, diagnostics, and interventions. It clarifies who does what, when, where, and in what order, providing clear guidance for both patients and the care team throughout the journey.

“Groupe Mutuel is convinced of the need to change the current healthcare system, which is reaching its limits, particularly in terms of financing. For several years now, we have been focusing on the importance of measuring outcomes that matter for the patients, quality of healthcare services, and possibilities of their optimisation. It was therefore obvious to address the theme of the patient journey and to support the approach proposed by Consulto.”, said Mikael Briguet, Head of APN & VBHC at Groupe Mutuel. 

Source: Consulto